ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 26 filers reported holding ASCENDIS PHARMA A/S in Q1 2016. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $397,127 | +59.1% | 4,241 | +51.7% | 0.08% | +83.3% |
Q2 2023 | $249,543 | +37.7% | 2,796 | +65.4% | 0.04% | +20.0% |
Q1 2023 | $181,202 | -12.2% | 1,690 | 0.0% | 0.04% | -12.5% |
Q4 2022 | $206,400 | +5.8% | 1,690 | -10.6% | 0.04% | +5.3% |
Q3 2022 | $195,000 | +10.8% | 1,890 | 0.0% | 0.04% | +8.6% |
Q2 2022 | $176,000 | -75.5% | 1,890 | -69.2% | 0.04% | -72.7% |
Q1 2022 | $719,000 | -12.8% | 6,129 | 0.0% | 0.13% | +3.2% |
Q4 2021 | $825,000 | -86.6% | 6,129 | -84.1% | 0.12% | -75.8% |
Q3 2021 | $6,160,000 | +1219.1% | 38,650 | +988.7% | 0.51% | +1247.4% |
Q2 2021 | $467,000 | +11.5% | 3,550 | +9.2% | 0.04% | +18.8% |
Q1 2021 | $419,000 | -27.4% | 3,250 | -89.5% | 0.03% | +14.3% |
Q1 2016 | $577,000 | +1.2% | 31,100 | 0.0% | 0.03% | +16.7% |
Q4 2015 | $570,000 | +3.6% | 31,100 | 0.0% | 0.02% | -4.0% |
Q3 2015 | $550,000 | -86.8% | 31,100 | -86.8% | 0.02% | -85.6% |
Q2 2015 | $4,165,000 | -67.2% | 235,560 | -67.8% | 0.17% | -63.9% |
Q1 2015 | $12,694,000 | – | 731,660 | – | 0.48% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |